Gantofiban manufacturers
- Gantofiban
-
- $81.00
-
2026-07-27
- CAS:183547-57-1
- Purity: 99.57%
- Supply Ability: 10g
|
| | Gantofiban Basic information |
| Product Name: | Gantofiban | | Synonyms: | Gantofiban;2-[4-[3-[4-[N1-(Methoxycarbonyl)amidino]phenyl]-2-oxooxazolidin-5(R)-ylmethyl]piperazin-1-yl]acetic acid ethyl ester;4-[[(5R)-3-[4-[Imino[(methoxycarbonyl)amino]methyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-1-piperazineacetic acid ethyl ester;EMD 151201;YNBHAPKHWDNTMZ-QGZVFWFLSA-N;1-Piperazineacetic acid, 4-[[(5R)-3-[4-[imino[(methoxycarbonyl)amino]methyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, ethyl ester | | CAS: | 183547-57-1 | | MF: | C21H29N5O6 | | MW: | 447.49 | | EINECS: | | | Product Categories: | | | Mol File: | 183547-57-1.mol |  |
| | Gantofiban Chemical Properties |
| density | 1.36±0.1 g/cm3(Predicted) | | pka | 9.53±0.46(Predicted) |
| | Gantofiban Usage And Synthesis |
| Uses | Gantofiban is a GPIIb/IIIa integrin receptor antagonist. By binding to this receptor, Gantofiban can effectively inhibit platelet aggregation, thereby exerting its antithrombotic effect[1]. | | References | [1] Schulte M, et al. Enantioseparation of gantofiban precursors on chiral stationary phases of the poly-(N-acryloyl amino acid derivative)-type. J Pharm Biomed Anal. 2002 Jan 15;27(3-4):627-37. DOI:10.1016/s0731-7085(01)00651-3 |
| | Gantofiban Preparation Products And Raw materials |
|